| |
news
* October 24 2022 - Simmunext Biotherapeutics to present at BIO-EUROPE conference
| |
Simmunext Biotherapeutics, a young biotech startup that is developing its proprietary immunofilaments technology platform, has been invited to speak at BIO-EUROPE, a global biopharma conference. Among some 2200 companies attending BIO-EUROPE this year, Simmunext has been selected to present in the Startup Spotlight session.
About Simmunext Biotherapeutics
As a spinoff from Oncode Institute and Radboudumc, Simmunext Biotherapeutics is developing a first-in-class off-the-shelf product to support or bypass adoptive cancer therapy (ACT) based on a filament-like semi-flexible PIC polymer backbone to which immune-modulating proteins are coupled. Using this technology platform, called ‘immunofilaments’, we generate bioconjugates that are able to stimulate immune cells in a manner similar to natural antigen presenting cells. Immunofilaments perform better than benchmark products in the ACT space. We obtained preclinical proof of concept convincingly and are preparing for FIH studies. |
* September 28 2022 - Holland Bio and Oncode Institute.
Carl Figdor presented at this BioTech event
* June 8 2022 -
Radboud University Simmunext: where immunotherapy and chemistry meet
* May 4 2022 - Oncode Institute Magazine
* March 11 2022 - simmunext is incorporated
|
